Skip to content

A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)

STRIDE II: A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System II

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06747117
Acronym
STRIDE II
Enrollment
300
Registered
2024-12-24
Start date
2025-05-18
Completion date
2029-01-01
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LE ALI, Lower Extremity Acute Limb Ischemia

Brief summary

The primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the Indigo™ Aspiration System in a patient population with lower extremity acute limb ischemia (LE ALI).

Interventions

Mechanical aspiration thrombectomy with the Indigo Aspiration System.

Sponsors

Penumbra Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Patients with a confirmed diagnosis of lower limb arterial occlusion located in the common iliac or below, with a minimum of 2 cm of proximal patency in the common iliac * Acute occlusion with symptom duration of 14 days or less at presentation * ALI Rutherford Category I, IIa or IIb * First-line treatment with the Indigo Aspiration System using Computer Assisted Vacuum Thrombectomy (CAVT) aspiration tubing * Informed consent is obtained from either patient or legally authorized representative (LAR) per Institutional Review Board/Ethics Committee requirements * Previously enrolled patients presenting with a new acute occlusion in the contralateral limb meeting all eligibility criteria may be re-enrolled if the new acute occlusion is greater than 30 days from the initial index procedure

Exclusion criteria

* Life expectancy \<1 year * Target vessel size \<2 mm * Target thrombus is in the aorta or isolated profunda artery * Prior major amputation (proximal to the tarsometatarsal joint) in the target limb * Prior minor amputation in the target limb within the past 6 months that is not completely healed or cannot bear weight * LE ALI secondary to dissection, vasculitis, or target vessel trauma, including iatrogenic etiology from treatment of a proximal location in the target limb, and non-thrombotic material such as tumor fragments, fat emboli, septic emboli, and foreign bodies * Target thrombus in a vein bypass graft, previously revised bypass grafts, bypass grafts placed \< 3 months prior to index ALI symptom onset, or bypass grafts with a distal anastomosis below the popliteal artery * Treatment of the index event with thrombolytics or any other endovascular or open surgical method prior to enrollment * Pregnancy * Contraindication or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated * Other medical, behavioral, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study * Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become

Design outcomes

Primary

MeasureTime frame
Target Limb Salvage Rate30 Days Post-Procedure

Secondary

MeasureTime frameDescription
Technical SuccessImmediate Post ProcedureTechnical success by treated segment defined as Thromboaspiration in Peripheral Ischemia (TIPI) 2/3 flow immediately post procedure by physician visual assessment of intraprocedural angiography
Primary Patency at 30 Days30 Days Post-Procedure
Rates of Device-related Major BleedingProcedure, 30 Days, and 180 Days Post-Procedure
Rates of Device-related Distal EmbolizationDuring Procedure
Rates of Device-related Serious Adverse Events (SAE)Procedure, 30 Days, and 180 Days Post-Procedure
Mortality30 Days and 180 Days Post-ProcedureAll cause mortality at 30 and 180 days

Countries

Australia, Brazil, Germany, Italy, Malaysia, Switzerland, United States

Contacts

CONTACTMarina Mello
mmello@penumbrainc.com+14078108634
CONTACTJemymah Allen
jallen@penumbrainc.com+13109485738
PRINCIPAL_INVESTIGATORDaniel Clair, MD

Vanderbilt University Medical Center

PRINCIPAL_INVESTIGATORDierk Scheinert, MD

Universitätsklinik Leipzig

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026